Please login to the form below
Teva and Novartis settle patent lawsuit
Teva Pharmaceuticals will settle patent litigation with Novartis involving Teva's US generic version of antiviral medication Famvir
Teva Pharmaceuticals, US, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of the Novartis-developed antiviral medication Famvir (famciclovir).
The settlement includes all claims for patent infringement and damages.
Under the terms of the agreement, Israel-based Teva will make an undisclosed one-time payment to Novartis plus ongoing royalties on US sales of its product, which is used to treat herpes and shingles.
Teva is among the top 15 global pharmaceutical companies and is a leading generic pharmaceutical company. Teva launched the generic version of Famvir in September 2007.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Manager
-
£Competitive Salary
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Director
-
£Competitive Salary
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Sanofi doses first patient in global Kevzara COVID-19 trial
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- Germany's coronavirus infections climb but deaths remain low
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- Novartis donates malaria drug for COVID-19 clinical trials
- Takeda begins development of COVID-19 plasma therapy
- Nurses on the frontline – World Health Day 2020
- We’re Celebrating Ten Magical Years for Ify at Lucid Group
- NICE publishes new COVID-19 management guidelines
- Servier agrees to buy Symphogen to swell its cancer pipeline
- FDA approves expanded use of BMS’ Reblozyl in blood disorders
- Key emerging trends in digital health
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- What challenges still face clinical trial recruitment and retention?
- Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
- “Fake News” and Credibility in Medical Publishing
- Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Quick links
Infographics
